{
    "clinical_study": {
        "@rank": "115911", 
        "arm_group": {
            "arm_group_label": "HaploSC+NK", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients\n      with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous\n      stem cell transplantation.\n\n      To evaluate feasibility and efficacy of NK cell infusion after haploidentical stem cell\n      transplantation in patients with high-risk solid tumors who failed after tandem high-dose\n      chemotherapy and autologous stem cell transplantation."
        }, 
        "brief_title": "Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuroblastoma", 
            "Ewing Sarcoma", 
            "Rhabdomyosarcoma", 
            "Osteosarcoma", 
            "Soft Tissue Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neuroblastoma", 
                "Osteosarcoma", 
                "Rhabdomyosarcoma", 
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "HaploSCT following reduced-intensity conditioning (RIC) regimen will be performed in\n      patients with high-risk solid tumors. Both parents will be evaluated for their KIR genotype\n      and phenotype and the one with the greatest degree of KIR-L mismatch with the patient will\n      be selected as the donor. In addition, ex-vivo expanded NK cells derived from the donor will\n      then be administered after haploSCT to increase the GVT effect. Low-dose IL-2 will be given\n      after expanded NK cell infusion to enhance NK cell alloreactivity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age < 21 years old\n\n          -  Patients with high-risk solid tumors who failed prior HDCT/autoSCT\n\n          -  Patients with a suitable haploidentical donor\n\n          -  High-risk solid tumors include high-risk neuroblastoma, metastatic or relapsed Ewing\n             sarcoma, relapsed osteosarcoma, high-risk brain tumors, relapsed germ cell tumors,\n             relapsed soft tissue sarcoma, relapsed rhabdomyosarcoma, and etc.\n\n          -  stable disease with salvage chemotherapy after relapse\n\n        Exclusion Criteria:\n\n          -  organ dysfunction(NCI common toxicity criteria grade > 2)\n\n          -  progression of disease despite salvage chemotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807468", 
            "org_study_id": "CR0113061"
        }, 
        "intervention": {
            "arm_group_label": "HaploSC+NK", 
            "intervention_name": "haploidentical stem cell transplantation and NK cell therapy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "haploidentical stem cell transplantation", 
            "natural killer cell therapy", 
            "pediatric solid tumor"
        ], 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "contact": {
                "last_name": "Ki Woong Sung, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Haploidentical Stem Cell Transplantation Followed by NK Cell Infusion in Patients With High-risk Solid Tumors Who Failed Autologous Stem Cell Transplantation", 
        "other_outcome": {
            "measure": "number of patients developing GVHD", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "overall_contact": {
            "email": "kwsped@skku.edu", 
            "last_name": "Ki Woong Sung, MD, PhD", 
            "phone": "82-2-3410-3529"
        }, 
        "overall_official": {
            "affiliation": "Department of Pediatrics, Samsung Medical Center", 
            "last_name": "Ki Woong Sung, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of study patients with adverse events as a measure of safety of haploidentical stem cell transplantation and NK cell infusion", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days after transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807468"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "KiWoong Sung", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "efficacy of haploidentical stem cell transplantation and NK cell infusion in patients with high-risk solid tumors", 
            "measure": "event-free survival and overall survival", 
            "safety_issue": "No", 
            "time_frame": "3 years after transplantation"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}